FDA
-
-
-
-
-
-
-
Jasper Therapeutics (JSPR) Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab
-
-
-
-
-
-
-
Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant
-
-
-
-
-
-
-
Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
-
-
-
323,584 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

